Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Cortexyme	Curis	Coherus BioSciences	Vaxcyte	Mesoblast
Symbol	NASDAQ:CRTX	NASDAQ:CRIS	NASDAQ:CHRS	NASDAQ:PCVX	NASDAQ:MESO
Price Information
Current Price	$36.35	$9.83	$14.08	$17.34	$6.75
52 Week Range	Hold	Buy	Buy	Buy	Hold
MarketRank™
Overall Score	1.6	1.3	1.4	1.7	1.4
Analysis Score	3.1	3.5	3.4	3.5	3.2
Community Score	2.6	2.6	2.5	2.9	3.1
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	2.5	0.0	0.0	1.7	0.0
Earnings & Valuation Score	0.0	0.6	1.3	0.6	0.6
Analyst Ratings
Consensus Recommendation	Hold	Buy	Buy	Buy	Hold
Consensus Price Target	$50.00	$14.60	$25.00	$48.00	$14.55
% Upside from Price Target	37.55% upside	48.52% upside	77.56% upside	176.82% upside	115.56% upside
Trade Information
Market Cap	$1.08 billion	$899.63 million	$1.07 billion	$890.50 million	$875.74 million
Beta	0.95	3.29	1.57	N/A	3.71
Average Volume	280,632	1,960,108	1,230,471	372,785	544,535
Sales & Book Value
Annual Revenue	N/A	$10 million	$356.07 million	N/A	$32.16 million
Price / Sales	N/A	89.96	3.00	N/A	27.23
Cashflow	N/A	N/A	$1.05 per share	N/A	N/A
Price / Cash	N/A	N/A	13.36	N/A	N/A
Book Value	$4.30 per share	($1.02) per share	$1.50 per share	N/A	$4.70 per share
Price / Book	N/A	-9.64	9.39	N/A	1.44
Profitability
Net Income	$-36,980,000.00	$-32,140,000.00	$89.83 million	$-50,270,000.00	$-77,940,000.00
EPS	($1.94)	($0.86)	$1.23	N/A	($0.74)
Trailing P/E Ratio	N/A	N/A	6.90	0.00	N/A
Forward P/E Ratio	N/A	N/A	16.00	N/A	N/A
P/E Growth	N/A	N/A	9.34	N/A	N/A
Net Margins	N/A	-279.33%	33.06%	N/A	-591.00%
Return on Equity (ROE)	-37.78%	N/A	90.98%	N/A	-18.69%
Return on Assets (ROA)	-35.24%	-81.32%	27.33%	N/A	-13.85%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	1.58%	N/A	0.10%
Current Ratio	8.71%	3.10%	5.45%	10.12%	1.32%
Quick Ratio	8.71%	3.10%	5.18%	10.12%	1.32%
Ownership Information
Institutional Ownership Percentage	55.48%	34.66%	N/A	74.08%	2.80%
Insider Ownership Percentage	19.80%	7.34%	15.86%	N/A	18.80%
Miscellaneous
Employees	37	28	310	58	102
Shares Outstanding	29.59 million	91.52 million	75.75 million	51.36 million	129.74 million
Next Earnings Date	8/16/2021 (Estimated)	5/12/2021 (Confirmed)	8/5/2021 (Estimated)	7/5/2021 (Estimated)	5/26/2021 (Estimated)
Optionable	Not Optionable	Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	Regenerative Therapies for Osteoarthritis Market SWOT Analysis including key players Acelity, Mesoblast, Nuo Therapeutics, Astellas Pharma – Jumbo News - Jumbo News jumbonews.co.uk - May 11 at 2:55 PM
	Adipose Derived Stem Cell Therapy Market – Major Technology Giants in Buzz Again \| AlloCure, Antria, Celgene Corporation, Cellleris – The Manomet Current - The Manomet Current manometcurrent.com - May 11 at 2:55 PM
	Mesoblast (NASDAQ:MESO) Hits New 52-Week Low at $6.88 americanbankingnews.com - May 11 at 10:39 AM
	Why does the Mesoblast (ASX:MSB) share price keep falling? - The Motley Fool Australia fool.com.au - May 11 at 9:51 AM
	Mesoblast (NASDAQ:MESO) Shares Gap Up to $6.98 americanbankingnews.com - May 10 at 2:45 PM
	MANA Therapeutics Appoints Arthur Hurwitz as Chief Scientific Officer - Joplin Globe joplinglobe.com - May 10 at 10:22 AM
	Rheumatoid Arthritis Stem Cell Therapy Market Is Booming Worldwide \| Mesoblast, Roslin Cells, Regeneus – Jumbo News - Jumbo News jumbonews.co.uk - May 10 at 10:22 AM
	Autologous Stem Cell Based Therapies Market 2021 Global Outlook – Regeneus, Mesoblast, Pluristem Therapeutics Inc, US STEM CELL, INC., Brainstorm Cell Therapeutics – The Shotcaller - The Shotcaller theshotcaller.net - May 9 at 7:31 AM
	Stocks That Hit 52-Week Lows On Friday Friday's morning session saw 17 companies set new - Benzinga benzinga.com - May 8 at 12:25 AM
	Asia-Pacific (APAC) Tissue Regenaration Market by Type, Application, Element – Global Trends and For - PharmiWeb.com pharmiweb.com - May 6 at 1:21 PM
	Analysts Offer Predictions for Mesoblast Limited's FY2022 Earnings (NASDAQ:MESO) americanbankingnews.com - May 6 at 11:12 AM
	15 recent ASC exec moves - Becker's ASC Review beckersasc.com - May 5 at 5:20 PM
	Remestemcel-L reduces ARDS mortality in those under 65 years old - European Pharmaceutical Review europeanpharmaceuticalreview.com - May 4 at 12:52 PM
	Investors Buy Large Volume of Call Options on Mesoblast (NASDAQ:MESO) americanbankingnews.com - May 4 at 6:56 AM
	Strength Seen in Mesoblast Limited (MESO): Can Its 6.1% Jump Turn into More Strength? - Yahoo Finance finance.yahoo.com - May 3 at 3:22 PM
	Is Mesoblast limited (MESO) Stock About to Get Hot Monday? - InvestorsObserver investorsobserver.com - May 3 at 3:22 PM
	Mesoblast (NASDAQ:MESO) Sets New 52-Week Low at $7.21 americanbankingnews.com - May 3 at 11:46 AM
	Stem Cells Market Size 2021 \| Is Expected to Showcase Considerable Growth by Reaching USD 27.65 Billion by 2028 While Exhibiting a CAGR of 12.8% between 2021 and 2028 - Stockhouse stockhouse.com - May 3 at 10:22 AM
	Global Autologous Stem Cell Based Therapies Market Revenue 2021 \| Regeneus, Mesoblast, Pluristem Therapeutics Inc – Jumbo News - Jumbo News jumbonews.co.uk - May 3 at 10:22 AM
	Umbilical Cord Blood (UCB) Stem Cell: Market – Recent Industry Developments and Growth Strategies Adopted by Top Players \| Mesoblast, Mesoblast Limited, California Stem Cell, Pluristem Therapeutics – Good News Gum - Good News Gum goodnewsgum.com - May 3 at 10:22 AM
	REMESTEMCEL-L REDUCES MORTALITY IN PATIENTS LESS THAN 65 YEARS OLD WITH MODERATE/SEVERE COVID-19 ARDS: TOPLINE 60-DAY RESULTS FROM RANDOMIZED CONTROLLED TRIAL - marketscreener.com marketscreener.com - May 3 at 10:22 AM
	Mesoblast's selective disclosure continues - The Australian Financial Review afr.com - May 3 at 10:22 AM
	Cord Blood Stem Cells Market 2021 Is Rapidly Increasing Worldwide in Near Future \| Top Companies Analysis- Advanced Cell Technology, California Stem Cell, Cytori Therapeutics, Mesoblast Limited, Opexa Therapeutics Inc., etc. - Good News Gum goodnewsgum.com - May 2 at 1:08 PM
	Stem Cells Market : Growth Factors and Competitive Players till 2026\| CELGENE CORPORATION, ReNeuron Group plc, Virgin Health Bank , Biovault family, Precious Cells International Ltd, Mesoblast Ltd - Good News Gum goodnewsgum.com - April 30 at 11:49 PM
	Mesoblast (ASX:MSB) study finds drug reduces mortality in COVID-19 ARDS patients under 65 - The Market Herald themarketherald.com.au - April 30 at 11:49 PM

Date	Company	Brokerage	Action
2/16/2021	Cortexyme	Jefferies Financial Group	Downgrade
12/11/2020	Cortexyme	Smith Barney Citigroup	Initiated Coverage
12/11/2020	Cortexyme	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage
12/7/2020	Cortexyme	Bank of America	Upgrade
9/24/2020	Cortexyme	Lifesci Capital	Reiterated Rating
6/24/2020	Cortexyme	HC Wainwright	Initiated Coverage
5/13/2020	Cortexyme	Canaccord Genuity	Reiterated Rating
6/3/2019	Cortexyme	Credit Suisse Group	Initiated Coverage
6/3/2019	Cortexyme	JMP Securities	Initiated Coverage
3/30/2021	Curis	B. Riley	Initiated Coverage
3/17/2021	Curis	Jonestrading	Boost Price Target
12/16/2020	Curis	Cantor Fitzgerald	Boost Price Target
7/29/2020	Curis	Laidlaw	Initiated Coverage
9/25/2018	Curis	Cowen	Reiterated Rating
8/3/2018	Curis	SunTrust Banks	Lower Price Target
5/7/2021	Coherus BioSciences	Maxim Group	Initiated Coverage
11/19/2020	Coherus BioSciences	Mizuho	Lower Price Target
2/6/2020	Coherus BioSciences	JPMorgan Chase & Co.	Boost Price Target
8/12/2019	Coherus BioSciences	Barclays	Set Price Target
8/14/2020	Vaxcyte	Needham & Company LLC	Reiterated Rating
12/4/2020	Mesoblast	Chardan Capital	Downgrade
10/22/2020	Mesoblast	Royal Bank of Canada	Initiated Coverage
5/28/2020	Mesoblast	LADENBURG THALM/SH SH	Boost Price Target
12/19/2019	Mesoblast	Dawson James	Initiated Coverage
9/10/2019	Mesoblast	Oppenheimer	Set Price Target

(Data available from 5/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources